Mouse anti-Human TIGIT Monoclonal Antibody | anti-TIGIT antibody

TIGIT

Cat. Num. AAA344147

• Reactivity: Human
• Synonyms: TIGIT; Monoclonal Antibody; anti-TIGIT antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG2a, kappa
• Form/Format: Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide

• Application Notes: 1:200
• Positive Control: Spleen
• Localization: Cytoplasmic
• Principles and Procedures: Visualization of the antigen present in tissue sections is accomplished in a multi-step immunohistochemical staining process, in conjunction with a horseradish peroxidase (HRP) or alkaline phosphatase (AP) linked detection system. The process involves the addition of the stated antibody (primary antibody) to a tissue slide, followed by a secondary antibody (linked to an enzyme complex) which specifically binds to the primary antibody. A chromogenic substrate is then added which reacts with the enzyme complex, resulting in a colorimetric reaction at the site of the antigen. Results are interpreted using a light microscope.
• Preparation and Storage: Store at 2-8 degree C.; To ensure stability, immediately replace vial back in the refrigerator after each use. When stored correctly, the antibody is stable until the expiry date indicated on the label.

Immunohistochemistry (IHC)

(TIGIT on Spleen)

Related Product Information for anti-TIGIT antibody

TIGIT is an immune receptor present on some T cells and Natural Killer cells. TIGIT binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Through the CD226/TIGIT-PVR pathway, TIGIT regulates T cell mediated immunity. In cancer, TIGIT and PD-1 have been shown to be over-expressed on tumor antigen-specific CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TILs) from individuals with melanoma. Blockade of TIGIT and PD-1 led to increased cell proliferation, cytokine production, and degranulation of tumour antigen-specific CD8+ T cells and TIL CD8+ T cells. It can be considered an immune checkpoint.